<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00710216</url>
  </required_header>
  <id_info>
    <org_study_id>EVD-001</org_study_id>
    <nct_id>NCT00710216</nct_id>
  </id_info>
  <brief_title>Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B</brief_title>
  <acronym>EVD</acronym>
  <official_title>Randomized, Open-Label, Phase IV Trial in Nucleus(t)id-Naive Patients With Chronic Hepatitis B to Examine the Effect of Telbivudine Compared to Lamivudine on the Early Dynamics and Kinetics of Viral Suppression (Early-Viral-Dynamics Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the effect of telbivudine compared to lamivudine on the early viral
      kinetics in patients with chronic hepatitis B. The virus Kinetics is measured by the viral
      load (HBV-DNA) reduction in the serum during the first 12 weeks of therapy.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor withdraw
  </why_stopped>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in viral load after 2 weeks of therapy measured in serum HBV-DNA concentration (Copies/ml or IU/ml).</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Course of the viral load (serum HBV-DNA) during the first 12 weeks of therapy</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of HBeAg status to the decrease in viral load</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of HBV genotype to the decrease in viral load</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ALT and AST levels from Baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of viral resistance and treatment failure during the study and subsequent course of observation</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by adverse events and laboratory values</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>100 mg/day</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Zeffix</other_name>
    <other_name>Epivir</other_name>
    <other_name>LAM</other_name>
    <other_name>134678-17-4</other_name>
    <other_name>J05AF05</other_name>
    <other_name>73339</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telbivudine</intervention_name>
    <description>600 mg/day</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Sebivo</other_name>
    <other_name>Tyzeka</other_name>
    <other_name>L-dT</other_name>
    <other_name>3424-98-4</other_name>
    <other_name>J05AF11</other_name>
    <other_name>159269</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented compensated HBeAg-positive or negative chronic hepatitis B

          -  Increased viral load with a concentration of serum HBV-DNA of at least 10^4 copies/ml

          -  Proof of inflammatory activity in the liver: ALT ≥ 2 x ULN or histological evidence of
             inflammatory activity ≥ level I or fibrosis of ≥ I degrees (according to the Desmet
             classification)

          -  Negative urine pregnancy test with fertile women

          -  Willingness to use a recognized method of contraception

          -  Able to comply with study regimen and provide written informed consent

        Exclusion Criteria:

          -  Current or previous antiviral treatment of chronic hepatitis B with Nucleus(t)id
             analoga

          -  Known hypersensitivity to lamivudine or telbivudine or any of the other components of
             the preparations

          -  Pregnant or breastfeeding women or women

          -  Simultaneous participation in other clinical trials or in the past three months

          -  Co-infected with HCV, HDV, HIV

          -  Other non HBV-related chronic liver disease: Autoimmune hepatitis, primary biliary
             cirrhosis, Hemochromatosis, alpha-1 antitrypsin deficiency, alcoholic hepatitis

          -  Evidence of hepatocellular carcinoma (alpha-fetoprotein levels&gt; 100 ng/ml)

          -  Active drug use, including an excessive alcohol consumption during the last 6 months
             before participating in the clinical trial

          -  Use of systemic treatment with anti-neoplastic or immunomodulatory medication within
             the last 6 months before participating in the clinical trial and during the duration
             of the clinical examination

          -  Lack of willingness or inability to consent in writing

          -  Concurrent condition likely to preclude compliance with schedule of evaluations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nektarios Dikopoulos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Ulm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.uniklinik-ulm.de/</url>
    <description>University Hospital Ulm</description>
  </link>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2008</study_first_submitted>
  <study_first_submitted_qc>July 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2008</study_first_posted>
  <last_update_submitted>April 16, 2009</last_update_submitted>
  <last_update_submitted_qc>April 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>PD Dr. med. Nektarios Dikopoulos</name_title>
    <organization>Universitätsklinikum Ulm</organization>
  </responsible_party>
  <keyword>Viral kinetics</keyword>
  <keyword>Viral dynamics</keyword>
  <keyword>Telbivudine</keyword>
  <keyword>Lamivudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Telbivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

